Loading…

A multifunctional therapeutic approach: Synthesis, biological evaluation, crystal structure and molecular docking of diversified 1H-pyrazolo[3,4-b]pyridine derivatives against Alzheimer's disease

2-(piperazin-1-yl)N-(1H-pyrazolo[3,4-b]pyridin-3-yl)acetamides are described as a new class of selective and potent acetylcholinesterase (AChE) inhibitors and amyloid β aggregation inhibitors. Formation of synthesized compounds (P1P9) was justified via H1 NMR, C13 NMR, mass spectra and single crysta...

Full description

Saved in:
Bibliographic Details
Published in:European journal of medicinal chemistry 2019-08, Vol.175, p.2-19
Main Authors: Umar, Tarana, Shalini, Shruti, Raza, Md Kausar, Gusain, Siddharth, Kumar, Jitendra, Seth, Prerna, Tiwari, Manisha, Hoda, Nasimul
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c408t-dd0cddae82a0b0a14d5ebaebbc459a8bb95d3fe45253629a970cb09e05e1add43
cites cdi_FETCH-LOGICAL-c408t-dd0cddae82a0b0a14d5ebaebbc459a8bb95d3fe45253629a970cb09e05e1add43
container_end_page 19
container_issue
container_start_page 2
container_title European journal of medicinal chemistry
container_volume 175
creator Umar, Tarana
Shalini, Shruti
Raza, Md Kausar
Gusain, Siddharth
Kumar, Jitendra
Seth, Prerna
Tiwari, Manisha
Hoda, Nasimul
description 2-(piperazin-1-yl)N-(1H-pyrazolo[3,4-b]pyridin-3-yl)acetamides are described as a new class of selective and potent acetylcholinesterase (AChE) inhibitors and amyloid β aggregation inhibitors. Formation of synthesized compounds (P1P9) was justified via H1 NMR, C13 NMR, mass spectra and single crystal X-Ray diffraction study. All compounds were evaluated for their acetylcholinesterase and butyrylcholinesterase inhibitory activity, inhibition of self-mediated Aβ aggregation and Cu(II)-mediated Aβ aggregation. Also, docking study carried out was in concordance with in vitro results. The most potent molecule amongst the derivatives exhibited excellent anti-AChE activity (IC50 = 4.8 nM). Kinetic study of P3 suggested it to be a mixed type inhibitor. In vitro study revealed that all the compounds are capable of inhibiting self-induced β-amyloid (Aβ) aggregation with the highest inhibition percentage to be 81.65%. Potency of P1 and P3 to inhibit self-induced Aβ1-42 aggregation was ascertained by TEM analysis. Compounds were also evaluated for their Aβ disaggregation, antioxidation, metal-chelation activity. [Display omitted] •2-(piperazin-1-yl)-N-(1H-pyrazolo[3,4-b]pyridin-3-yl)acetamides are described as new multifunctional anti-Alzheimer’s agents.•They possess AChE and BChE inhibition, Aβ aggregation inhibition, Aβ disaggregation, antioxidation and metal-chelation properties.•The most potent molecule amongst the derivatives exhibited excellent anti-AChE activity with IC50 = 4.8 nM.•In vitro study revealed compounds to be capable of inhibiting self-induced β-amyloid aggregation with the highest inhibition percentage 81.65%.•Aβ1-42 aggregation was ascertained by TEM analysis.
doi_str_mv 10.1016/j.ejmech.2019.04.038
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2231916213</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0223523419303538</els_id><sourcerecordid>2231916213</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-dd0cddae82a0b0a14d5ebaebbc459a8bb95d3fe45253629a970cb09e05e1add43</originalsourceid><addsrcrecordid>eNp9kc-O0zAQxiMEYsvCGyDkGxyaME7sbsMBqVoBi7QSB-CEkDWxJ-2U_OnaTqTu6_FiuOrCkdPI49_3jWa-LHspoZAgV2_3Be17sruiBFkXoAqo1o-yhbxarfOq1OpxtoCyrHJdVuoiexbCHgD0CuBpdlFJ0FqqepH93oh-6iK302AjjwN2Iu7I44GmyFbg4eBHtLt34utxSB-Bw1I0PHbjlm1iacZuwpNwKaw_hph6IfrJxsmTwMGJfuzITh164Ub7i4etGFvheCYfuGVyQt7kh6PH--T5o1qqvPmZnux4IOHI85zcZwoCt8hDiGLT3e-Ie_KvQ7IJhIGeZ09a7AK9eKiX2fePH75d3-S3Xz59vt7c5lbBOubOgXUOaV0iNIBSOU0NUtNYpWtcN02tXdWS0qWuVmWN9RXYBmoCTRKdU9Vl9ubsm25yN1GIpudgqetwoHEKJl1b1nJVyiqh6oxaP4bgqTUHzz36o5FgTvGZvTnHZ07xGVAmxZdkrx4mTE1P7p_ob14JeH8GKO05M3kTLNNgybEnG40b-f8T_gDvB7Rw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2231916213</pqid></control><display><type>article</type><title>A multifunctional therapeutic approach: Synthesis, biological evaluation, crystal structure and molecular docking of diversified 1H-pyrazolo[3,4-b]pyridine derivatives against Alzheimer's disease</title><source>Elsevier</source><creator>Umar, Tarana ; Shalini, Shruti ; Raza, Md Kausar ; Gusain, Siddharth ; Kumar, Jitendra ; Seth, Prerna ; Tiwari, Manisha ; Hoda, Nasimul</creator><creatorcontrib>Umar, Tarana ; Shalini, Shruti ; Raza, Md Kausar ; Gusain, Siddharth ; Kumar, Jitendra ; Seth, Prerna ; Tiwari, Manisha ; Hoda, Nasimul</creatorcontrib><description>2-(piperazin-1-yl)N-(1H-pyrazolo[3,4-b]pyridin-3-yl)acetamides are described as a new class of selective and potent acetylcholinesterase (AChE) inhibitors and amyloid β aggregation inhibitors. Formation of synthesized compounds (P1P9) was justified via H1 NMR, C13 NMR, mass spectra and single crystal X-Ray diffraction study. All compounds were evaluated for their acetylcholinesterase and butyrylcholinesterase inhibitory activity, inhibition of self-mediated Aβ aggregation and Cu(II)-mediated Aβ aggregation. Also, docking study carried out was in concordance with in vitro results. The most potent molecule amongst the derivatives exhibited excellent anti-AChE activity (IC50 = 4.8 nM). Kinetic study of P3 suggested it to be a mixed type inhibitor. In vitro study revealed that all the compounds are capable of inhibiting self-induced β-amyloid (Aβ) aggregation with the highest inhibition percentage to be 81.65%. Potency of P1 and P3 to inhibit self-induced Aβ1-42 aggregation was ascertained by TEM analysis. Compounds were also evaluated for their Aβ disaggregation, antioxidation, metal-chelation activity. [Display omitted] •2-(piperazin-1-yl)-N-(1H-pyrazolo[3,4-b]pyridin-3-yl)acetamides are described as new multifunctional anti-Alzheimer’s agents.•They possess AChE and BChE inhibition, Aβ aggregation inhibition, Aβ disaggregation, antioxidation and metal-chelation properties.•The most potent molecule amongst the derivatives exhibited excellent anti-AChE activity with IC50 = 4.8 nM.•In vitro study revealed compounds to be capable of inhibiting self-induced β-amyloid aggregation with the highest inhibition percentage 81.65%.•Aβ1-42 aggregation was ascertained by TEM analysis.</description><identifier>ISSN: 0223-5234</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2019.04.038</identifier><identifier>PMID: 31055149</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>AChE inhibitors ; Amyloid β aggregation inhibitors ; Docking ; N-(1H-pyrazolo[3,4-b]pyridin-3-yl)acetamides ; Selectivity</subject><ispartof>European journal of medicinal chemistry, 2019-08, Vol.175, p.2-19</ispartof><rights>2019 Elsevier Masson SAS</rights><rights>Copyright © 2019 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-dd0cddae82a0b0a14d5ebaebbc459a8bb95d3fe45253629a970cb09e05e1add43</citedby><cites>FETCH-LOGICAL-c408t-dd0cddae82a0b0a14d5ebaebbc459a8bb95d3fe45253629a970cb09e05e1add43</cites><orcidid>0000-0002-9175-198X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31055149$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Umar, Tarana</creatorcontrib><creatorcontrib>Shalini, Shruti</creatorcontrib><creatorcontrib>Raza, Md Kausar</creatorcontrib><creatorcontrib>Gusain, Siddharth</creatorcontrib><creatorcontrib>Kumar, Jitendra</creatorcontrib><creatorcontrib>Seth, Prerna</creatorcontrib><creatorcontrib>Tiwari, Manisha</creatorcontrib><creatorcontrib>Hoda, Nasimul</creatorcontrib><title>A multifunctional therapeutic approach: Synthesis, biological evaluation, crystal structure and molecular docking of diversified 1H-pyrazolo[3,4-b]pyridine derivatives against Alzheimer's disease</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>2-(piperazin-1-yl)N-(1H-pyrazolo[3,4-b]pyridin-3-yl)acetamides are described as a new class of selective and potent acetylcholinesterase (AChE) inhibitors and amyloid β aggregation inhibitors. Formation of synthesized compounds (P1P9) was justified via H1 NMR, C13 NMR, mass spectra and single crystal X-Ray diffraction study. All compounds were evaluated for their acetylcholinesterase and butyrylcholinesterase inhibitory activity, inhibition of self-mediated Aβ aggregation and Cu(II)-mediated Aβ aggregation. Also, docking study carried out was in concordance with in vitro results. The most potent molecule amongst the derivatives exhibited excellent anti-AChE activity (IC50 = 4.8 nM). Kinetic study of P3 suggested it to be a mixed type inhibitor. In vitro study revealed that all the compounds are capable of inhibiting self-induced β-amyloid (Aβ) aggregation with the highest inhibition percentage to be 81.65%. Potency of P1 and P3 to inhibit self-induced Aβ1-42 aggregation was ascertained by TEM analysis. Compounds were also evaluated for their Aβ disaggregation, antioxidation, metal-chelation activity. [Display omitted] •2-(piperazin-1-yl)-N-(1H-pyrazolo[3,4-b]pyridin-3-yl)acetamides are described as new multifunctional anti-Alzheimer’s agents.•They possess AChE and BChE inhibition, Aβ aggregation inhibition, Aβ disaggregation, antioxidation and metal-chelation properties.•The most potent molecule amongst the derivatives exhibited excellent anti-AChE activity with IC50 = 4.8 nM.•In vitro study revealed compounds to be capable of inhibiting self-induced β-amyloid aggregation with the highest inhibition percentage 81.65%.•Aβ1-42 aggregation was ascertained by TEM analysis.</description><subject>AChE inhibitors</subject><subject>Amyloid β aggregation inhibitors</subject><subject>Docking</subject><subject>N-(1H-pyrazolo[3,4-b]pyridin-3-yl)acetamides</subject><subject>Selectivity</subject><issn>0223-5234</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kc-O0zAQxiMEYsvCGyDkGxyaME7sbsMBqVoBi7QSB-CEkDWxJ-2U_OnaTqTu6_FiuOrCkdPI49_3jWa-LHspoZAgV2_3Be17sruiBFkXoAqo1o-yhbxarfOq1OpxtoCyrHJdVuoiexbCHgD0CuBpdlFJ0FqqepH93oh-6iK302AjjwN2Iu7I44GmyFbg4eBHtLt34utxSB-Bw1I0PHbjlm1iacZuwpNwKaw_hph6IfrJxsmTwMGJfuzITh164Ub7i4etGFvheCYfuGVyQt7kh6PH--T5o1qqvPmZnux4IOHI85zcZwoCt8hDiGLT3e-Ie_KvQ7IJhIGeZ09a7AK9eKiX2fePH75d3-S3Xz59vt7c5lbBOubOgXUOaV0iNIBSOU0NUtNYpWtcN02tXdWS0qWuVmWN9RXYBmoCTRKdU9Vl9ubsm25yN1GIpudgqetwoHEKJl1b1nJVyiqh6oxaP4bgqTUHzz36o5FgTvGZvTnHZ07xGVAmxZdkrx4mTE1P7p_ob14JeH8GKO05M3kTLNNgybEnG40b-f8T_gDvB7Rw</recordid><startdate>20190801</startdate><enddate>20190801</enddate><creator>Umar, Tarana</creator><creator>Shalini, Shruti</creator><creator>Raza, Md Kausar</creator><creator>Gusain, Siddharth</creator><creator>Kumar, Jitendra</creator><creator>Seth, Prerna</creator><creator>Tiwari, Manisha</creator><creator>Hoda, Nasimul</creator><general>Elsevier Masson SAS</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9175-198X</orcidid></search><sort><creationdate>20190801</creationdate><title>A multifunctional therapeutic approach: Synthesis, biological evaluation, crystal structure and molecular docking of diversified 1H-pyrazolo[3,4-b]pyridine derivatives against Alzheimer's disease</title><author>Umar, Tarana ; Shalini, Shruti ; Raza, Md Kausar ; Gusain, Siddharth ; Kumar, Jitendra ; Seth, Prerna ; Tiwari, Manisha ; Hoda, Nasimul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-dd0cddae82a0b0a14d5ebaebbc459a8bb95d3fe45253629a970cb09e05e1add43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>AChE inhibitors</topic><topic>Amyloid β aggregation inhibitors</topic><topic>Docking</topic><topic>N-(1H-pyrazolo[3,4-b]pyridin-3-yl)acetamides</topic><topic>Selectivity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Umar, Tarana</creatorcontrib><creatorcontrib>Shalini, Shruti</creatorcontrib><creatorcontrib>Raza, Md Kausar</creatorcontrib><creatorcontrib>Gusain, Siddharth</creatorcontrib><creatorcontrib>Kumar, Jitendra</creatorcontrib><creatorcontrib>Seth, Prerna</creatorcontrib><creatorcontrib>Tiwari, Manisha</creatorcontrib><creatorcontrib>Hoda, Nasimul</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Umar, Tarana</au><au>Shalini, Shruti</au><au>Raza, Md Kausar</au><au>Gusain, Siddharth</au><au>Kumar, Jitendra</au><au>Seth, Prerna</au><au>Tiwari, Manisha</au><au>Hoda, Nasimul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A multifunctional therapeutic approach: Synthesis, biological evaluation, crystal structure and molecular docking of diversified 1H-pyrazolo[3,4-b]pyridine derivatives against Alzheimer's disease</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2019-08-01</date><risdate>2019</risdate><volume>175</volume><spage>2</spage><epage>19</epage><pages>2-19</pages><issn>0223-5234</issn><eissn>1768-3254</eissn><abstract>2-(piperazin-1-yl)N-(1H-pyrazolo[3,4-b]pyridin-3-yl)acetamides are described as a new class of selective and potent acetylcholinesterase (AChE) inhibitors and amyloid β aggregation inhibitors. Formation of synthesized compounds (P1P9) was justified via H1 NMR, C13 NMR, mass spectra and single crystal X-Ray diffraction study. All compounds were evaluated for their acetylcholinesterase and butyrylcholinesterase inhibitory activity, inhibition of self-mediated Aβ aggregation and Cu(II)-mediated Aβ aggregation. Also, docking study carried out was in concordance with in vitro results. The most potent molecule amongst the derivatives exhibited excellent anti-AChE activity (IC50 = 4.8 nM). Kinetic study of P3 suggested it to be a mixed type inhibitor. In vitro study revealed that all the compounds are capable of inhibiting self-induced β-amyloid (Aβ) aggregation with the highest inhibition percentage to be 81.65%. Potency of P1 and P3 to inhibit self-induced Aβ1-42 aggregation was ascertained by TEM analysis. Compounds were also evaluated for their Aβ disaggregation, antioxidation, metal-chelation activity. [Display omitted] •2-(piperazin-1-yl)-N-(1H-pyrazolo[3,4-b]pyridin-3-yl)acetamides are described as new multifunctional anti-Alzheimer’s agents.•They possess AChE and BChE inhibition, Aβ aggregation inhibition, Aβ disaggregation, antioxidation and metal-chelation properties.•The most potent molecule amongst the derivatives exhibited excellent anti-AChE activity with IC50 = 4.8 nM.•In vitro study revealed compounds to be capable of inhibiting self-induced β-amyloid aggregation with the highest inhibition percentage 81.65%.•Aβ1-42 aggregation was ascertained by TEM analysis.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>31055149</pmid><doi>10.1016/j.ejmech.2019.04.038</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0002-9175-198X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0223-5234
ispartof European journal of medicinal chemistry, 2019-08, Vol.175, p.2-19
issn 0223-5234
1768-3254
language eng
recordid cdi_proquest_miscellaneous_2231916213
source Elsevier
subjects AChE inhibitors
Amyloid β aggregation inhibitors
Docking
N-(1H-pyrazolo[3,4-b]pyridin-3-yl)acetamides
Selectivity
title A multifunctional therapeutic approach: Synthesis, biological evaluation, crystal structure and molecular docking of diversified 1H-pyrazolo[3,4-b]pyridine derivatives against Alzheimer's disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T18%3A45%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20multifunctional%20therapeutic%20approach:%20Synthesis,%20biological%20evaluation,%20crystal%20structure%20and%20molecular%20docking%20of%20diversified%201H-pyrazolo%5B3,4-b%5Dpyridine%20derivatives%20against%20Alzheimer's%20disease&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=Umar,%20Tarana&rft.date=2019-08-01&rft.volume=175&rft.spage=2&rft.epage=19&rft.pages=2-19&rft.issn=0223-5234&rft.eissn=1768-3254&rft_id=info:doi/10.1016/j.ejmech.2019.04.038&rft_dat=%3Cproquest_cross%3E2231916213%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c408t-dd0cddae82a0b0a14d5ebaebbc459a8bb95d3fe45253629a970cb09e05e1add43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2231916213&rft_id=info:pmid/31055149&rfr_iscdi=true